RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20 AUG 90

File: 120396_sep96_decls54_0011.txt
Page: 0011
Total Pages: 16

Subject: RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20 AUG 90          

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003201

Folder Title: OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT                            

Document Number:          1

Folder SEQ  #:         45






         Reactogenicity is modest, with 2-4% of vaccinees reporting erythema, edema,
         or induration which peaks at 24-48 hours, then dissipates. The frequency of
         local reactions increases with each subsequent inoculation; after the second and
         third doses, 7-10% will have local reactions, with higher incidences (up to 20%
         or so) after boosters. Severe local reactions are rare, consisting of more
         extensive edema or induration. Systemic reactions are reported in up to 3%,
         consisting of fever, malaise, headache, and Tyalgia. Incapacitating reactions
         (local or systemic) are uncommon. The vaccine must be stored at refrigerator
         temperatures n@ frozen).
               Given current and projected vaccine stocks, we recommend
         administration of 2 or more vaccine doses (days 0, 14, 84, and 365 if possible,
         by d= subcutaneous injection) to only selected individuals or groups.

               ANTITOXIN

               A human pentavalent antitoxin produced by plasmapheresis of toxoid
         vaccinees has been produced, and is available in MM limited quantities. It is
         carried as an IND product, currently available under protocol, and has never
         been tested for efficacy. Neither formal safety nor pharmacokinetic studies
         have been performed. We view this product as useful only for highly
         specialized indications, and should not be considered as generally available.
         There is essentially no prospect for additional human antitoxin to be produced

         and made available in the foreseeable future.



               POST-EXPOSURE

               In addition to the human pentavalent antitoxin described above, equine
         trivalent (vs types A, B, and E) antitoxin, commercially produced by
         Connaught Laboratories, is available for post-exposure prophylaxis. This
                                                        DRo4FT

Document 16 f:/Week-36/BX003201/OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT/response to the biological warfare bw threat 20 :11229616342212
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT
Folder Seq # = 45
Subject = RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 22-NOV-1996